{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:16:23Z","timestamp":1777907783892,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Pharmacopsychiatry"],"abstract":"<jats:p>Psychotropic drugs are used frequently for the treatment of emotional as\nwell as other disorders. With usage so widespread, many pregnant women receive psychotropic\ndrugs. Maternal ingestion of these drugs may produce, in the fetus, side effects\nincluding withdrawal symptoms. Withdrawal signs in the fetus as a result of maternal intake\nof opiates, hypnotics, analgesics, and tricyclic antidepressant drugs have been reported.\nFetal side effects can occur by maternal ingestion of nuroleptic medications, lithium, antidepressants,\nanxiolytic sedatives, anticonvulsants, and bromides. The author feels that even\nthough these drugs are generally safe, they must only be administered to pregnant women\nwhen absolutely needed, and then under vigilance.<\/jats:p>","DOI":"10.1159\/000468239","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:20:14Z","timestamp":1502472014000},"page":"246-260","source":"Crossref","is-referenced-by-count":33,"title":["Side Effects on Fetus and Infant of Psychotropic Drug Use\nduring Pregnancy"],"prefix":"10.1159","author":[{"given":"J.","family":"Ananth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["International Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000468239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:47:03Z","timestamp":1777643223000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000468239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000468239","archive":["Portico"],"relation":{},"ISSN":["0020-8272","2504-2580"],"issn-type":[{"value":"0020-8272","type":"print"},{"value":"2504-2580","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}